20 most recent filings and news items mentioning ABBV. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/ABBV/news?limit=20"
Pull ABBV filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
View filing at SEC.gov →AbbVie priced $12.05 billion in aggregate face value of senior notes across multiple series, arranged by Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC, and SG Americas Securities, LLC.
View filing at SEC.gov →AbbVie reported Q2 2026 net revenues of $16.99 billion, a 10.2% increase, and updated its adjusted EPS guidance to $13.87-$14.07.
View filing at SEC.gov →Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'
View filing at SEC.gov →Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
View filing at SEC.gov →UnitedHealth Rally Sparks Bullish Case for Healthcare ETFs Despite Medicare Advantage Losses
View filing at SEC.gov →6 Health Care Stocks With Whale Alerts In Today’s Session
View filing at SEC.gov →Rick Scott Urges Trump to Increase Tariffs on Chinese Generic Drug Makers Over 'Uyghur Slave Labor' Claims
View filing at SEC.gov →AbbVie Inc. announced revised adjusted diluted EPS guidance of $13.91 to $14.11 for full-year 2026. The updated outlook incorporates a $291 million expense for acquired IPR&D and milestones, slightly lowering expectations from prior forecasts.
View filing at SEC.gov →Reuters Reported AbbVie, Merck Face U.S. House Committee National Security Investigation Into China Drug Trials To Determine If They Fueled China's Military Capabilities
View filing at SEC.gov →U.S. House Committee Opens Probe Into Merck And AbbVie Drug Trials In China
View filing at SEC.gov →Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report
View filing at SEC.gov →U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials
View filing at SEC.gov →Live On CNBC, Kevin Simpson Announces Bought More AbbVie; Bought More Amgen
View filing at SEC.gov →AbbVie Inc. has entered into a definitive merger agreement to acquire Apogee Therapeutics, Inc. through a subsidiary merger structure. The transaction expands AbbVie's therapeutic pipeline and represents a significant M&A activity in the pharmaceutical sector.
View filing at SEC.gov →AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share, totaling approximately $10.9 billion in equity value. The acquisition adds a clinical-stage immunology pipeline focused on inflammatory and immunological diseases including atopic dermat
View filing at SEC.gov →AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
View filing at SEC.gov →7 Health Care Stocks With Whale Alerts In Today's Session
View filing at SEC.gov →AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'
View filing at SEC.gov →CNBC Halftime Report Final Trades: Coca-Cola, AbbVie, UnitedHealth Group, Sabra Health Care REIT
View filing at SEC.gov →